Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 25, Issue 20, Pages 2524-2538
Publisher
Baishideng Publishing Group Inc.
Online
2019-05-28
DOI
10.3748/wjg.v25.i20.2524
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study
- (2018) Cheng-Maw Ho et al. BMC CANCER
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B
- (2018) Sameh Saber et al. TOXICOLOGY LETTERS
- The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival
- (2017) Taejong Song et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma
- (2017) Jean-Luc Raoul et al. EXPERT OPINION ON PHARMACOTHERAPY
- Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest
- (2017) Kyoko Oura et al. ONCOLOGY REPORTS
- Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma
- (2017) Matthias Pinter et al. United European Gastroenterology Journal
- The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level
- (2017) et al. JAMA Oncology
- Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon
- (2016) S. Petta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway
- (2016) Fangtian Fan et al. BIOMEDICINE & PHARMACOTHERAPY
- Clinical implications of basic research in hepatocellular carcinoma
- (2016) Renumathy Dhanasekaran et al. JOURNAL OF HEPATOLOGY
- Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the UK Clinical Practice Research Datalink
- (2016) Katrina Wilcox Hagberg et al. PHARMACOTHERAPY
- Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma
- (2016) Massimiliano Berretta et al. Frontiers in Pharmacology
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients
- (2015) Antonio Facciorusso et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma
- (2015) Antonio Facciorusso et al. Expert Review of Gastroenterology & Hepatology
- Olive oil and omega-3 polyunsaturated fatty acids suppress intestinal polyp growth by modulating the apoptotic process in ApcMin/+ mice
- (2014) Michele Barone et al. CARCINOGENESIS
- Effects of Angiotensin II Type 2 Receptor Overexpression on the Growth of Hepatocellular Carcinoma Cells In Vitro and In Vivo
- (2014) Hongyan Du et al. PLoS One
- Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGFβ signaling
- (2014) Prasanna K. Santhekadur et al. FEBS Open Bio
- Bone marrow-derived stem cells and hepatocarcinogenesis in hepatitis B virus transgenic mice
- (2013) Michele Barone et al. DIGESTIVE AND LIVER DISEASE
- Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice
- (2013) Magda Nasr et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Telmisartan Inhibits Cell Proliferation by Blocking Nuclear Translocation of ProHB-EGF C-Terminal Fragment in Colon Cancer Cells
- (2013) Keiji Ozeki et al. PLoS One
- Possible Involvement of Angiogenesis in Chronic Liver Diseases: Interaction Among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress
- (2012) K. Kaji et al. CURRENT MEDICINAL CHEMISTRY
- Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis
- (2012) Ryuichi Noguchi et al. HEPATOLOGY RESEARCH
- Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection
- (2012) Yu-Tse Tsan et al. JOURNAL OF CLINICAL ONCOLOGY
- Statins and Risk Reduction in Hepatocellular Carcinoma: Fact or Fiction?
- (2012) Preet Paul Singh et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis
- (2012) Yosui Tamaki et al. JOURNAL OF GASTROENTEROLOGY
- Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database
- (2011) Alex J. Walker et al. CANCER CAUSES & CONTROL
- Comparison of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockade for the prevention of premalignant changes in the liver
- (2011) Mahmoud A. Mansour et al. LIFE SCIENCES
- Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: A randomized control trial
- (2011) Hitoshi Yoshiji ONCOLOGY REPORTS
- Evaluation of metabolic factors on the prognosis of patients undergoing resection of hepatocellular carcinoma
- (2010) Masaki Kaibori et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents
- (2010) HITOSHI YOSHIJI et al. Oncology Letters
- Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats
- (2009) Hitoshi Yoshiji et al. JOURNAL OF GASTROENTEROLOGY
- Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma
- (2009) Hitoshi Yoshiji et al. JOURNAL OF HEPATOLOGY
- The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C
- (2009) Kathleen E. Corey et al. LIVER INTERNATIONAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More